Navigation Links
Telik Reports Positive Data Demonstrating Synergy in Combination,and Highly Statistically Significant Effect of Telcyta as,Maintenance Therapy in First-Line Non-Small Cell Lung Cancer

PALO ALTO, Calif., April 17, 2007 /PRNewswire-FirstCall/ -- Telik, Inc. announced the presentation today of results from a Phase 2 clinical trial of the triplet combination of TELCYTA(R) (canfosfamide HCl, TLK286), carboplatin and paclitaxel in the first-line treatment of advanced non-small cell lung cancer. The results include highly statistically and clinically significant improvement in both progression-free survival and overall survival in responding patients who received TELCYTA maintenance therapy as compared with those who did not receive TELCYTA maintenance therapy. The data were presented at the 98th annual meeting of the American Association for Cancer Research (AACR) in Los Angeles.

The multicenter dose-ranging study enrolled 129 patients with Stage IIIB or IV non-small cell lung cancer. Patients received standard doses of carboplatin and paclitaxel and one of four doses of TELCYTA (400, 500, 750 or 1,000 mg/m2) for a planned course of four to six cycles. Patients with objective responses or stable disease following completion of combination therapy could elect to receive every three week maintenance cycles of TELCYTA as monotherapy until disease progression. Outcomes to be evaluated included safety, objective response and disease stabilization rates, progression-free survival and overall survival in the intent-to-treat population, and safety, progression-free survival and overall survival in patients receiving TELCYTA maintenance therapy.

In the intent-to-treat population (n = 129), the overall objective response rate was 34% (95% CI 26%, 43%), including one complete response. Fifty-six patients, or 43%, had disease stabilization, for an overall disease stabilization rate of 77% (95% CI 69%, 84%). Median progression-free survival was 4.9 months, and the overall median survival was 9.6 months.

One hundred patients (77% of enrolled patients) had objective responses or stable disea
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Telik Announces Telcyta Clinical and Preclinical Presentations at AACR Meeting
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
10. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
11. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
Post Your Comments:
(Date:5/30/2015)... SPARTANBURG , Carolina del Sur , ... Nueva colaboración para ampliar drásticamente el acceso al ... los Estados Unidos   La ... los pacientes con cáncer apoyo de decisión clínica ... y Molecular Health han anunciado una colaboración diseñada ...
(Date:5/30/2015)... 30, 2015  Eisai Inc. announced today the results of ... met the study,s primary endpoint evaluating overall survival in patients ... types of advanced soft tissue sarcoma. These data will be ... American Society of Clinical Oncology (ASCO) in Chicago ... Saturday, May 30, and also in an oral session on ...
(Date:5/30/2015)... 2015 Caris Life Sciences®, a leading ... precision medicine, today announced the presentation of data ... Caris Molecular Intelligence®, the company,s panomic comprehensive tumor ... share histological features. In separate presentations at the ... Oncology (ASCO) in Chicago, Ill. ...
Breaking Medicine Technology:Nueva colaboración para ampliar el acceso al ensayo clínico terapéutico para pacientes con cáncer en EEUU 2Nueva colaboración para ampliar el acceso al ensayo clínico terapéutico para pacientes con cáncer en EEUU 3Nueva colaboración para ampliar el acceso al ensayo clínico terapéutico para pacientes con cáncer en EEUU 4Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 2Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 3Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 4Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 5Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 6Caris Molecular Intelligence Multi-Platform Tumor Profiling Facilitates Comparisons between Tumors that Share Histological Features 2Caris Molecular Intelligence Multi-Platform Tumor Profiling Facilitates Comparisons between Tumors that Share Histological Features 3Caris Molecular Intelligence Multi-Platform Tumor Profiling Facilitates Comparisons between Tumors that Share Histological Features 4Caris Molecular Intelligence Multi-Platform Tumor Profiling Facilitates Comparisons between Tumors that Share Histological Features 5Caris Molecular Intelligence Multi-Platform Tumor Profiling Facilitates Comparisons between Tumors that Share Histological Features 6
... - Initial clinical trial results suggesting safety and ... the AACR-NCI-EORTC International Conference -, BRANFORD, Conn., ... a clinical-stage biopharmaceutical company focused on,oncology, announced that ... CR011-,vcMMAE, an antibody-drug conjugate (ADC) being developed for ...
... of Two Major Clinical Studies TAX 323 and ... Sanofi-aventis,announced today that results of two clinical ... to cisplatin and,5- fluorouracil for induction therapy, significantly ... squamous cell carcinoma of,the head and neck (SCCHN) ...
Cached Medicine Technology:CuraGen Announces Presentation of Phase I Dose-Escalation Results on CR011- vcMMAE for Metastatic Melanoma 2CuraGen Announces Presentation of Phase I Dose-Escalation Results on CR011- vcMMAE for Metastatic Melanoma 3CuraGen Announces Presentation of Phase I Dose-Escalation Results on CR011- vcMMAE for Metastatic Melanoma 4CuraGen Announces Presentation of Phase I Dose-Escalation Results on CR011- vcMMAE for Metastatic Melanoma 5CuraGen Announces Presentation of Phase I Dose-Escalation Results on CR011- vcMMAE for Metastatic Melanoma 6Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine 2Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine 3Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine 4Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine 5Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine 6Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine 7
(Date:5/30/2015)... 30, 2015 Nicole Blodgett, Vice ... Income Associate (DIA) designation to further her expertise ... is designed for insurance advisors, health care professionals, ... knowledge and expertise associated with the risk and ... designation is only the latest accomplishment in Nicole's ...
(Date:5/30/2015)... 30, 2015 Cyclist Barry Haarde ... for the World 2015: Piles of Miles” near ... awareness about hemophilia and encourage individuals to support ... , Save One Life supports nearly 1,200 impoverished ... countries through direct sponsorships, scholarships and micro-enterprise grants. ...
(Date:5/30/2015)... CA (PRWEB) May 30, 2015 Key ... California, is proud to announce their June 2015 featured ... apartment community in San Francisco, Key Housing is helping ... housing in what is one of the tightest apartment ... a plum posting, and understandably anyone who requires temporary ...
(Date:5/30/2015)... “ Milli the Snail ” was featured on ... look at the latest and coolest applications on the market ... AppWatch and technology expert, conducted the app review and shared ... and educates children. , Interactive mobile games for children have ... and games they are playing are doing much for their ...
(Date:5/30/2015)... York, NY (PRWEB) May 30, 2015 ... Wednesday, May 26th 2015, announcing that, “criminals used taxpayer-specific ... to information on approximately 100,000 tax accounts through IRS’ ... date of birth and street address.” , “You ... industry to have to think it was only a ...
Breaking Medicine News(10 mins):Health News:Secura Consultants Expands Disability Insurance Expertise 2Health News:Barry Haarde Cycles 4,000 Miles Across the USA for Hemophilia 2Health News:San Francisco Corporate Housing Leader Key Housing Designates 388 Beale Street as Featured Community for June 2Health News:San Francisco Corporate Housing Leader Key Housing Designates 388 Beale Street as Featured Community for June 3Health News:An Aesthetic Game that Engages and Educates Children was Featured on NewsWatch Television 2Health News:IRS Attack Exemplifies the Compounding Dangers of Stolen Personal Data 2Health News:IRS Attack Exemplifies the Compounding Dangers of Stolen Personal Data 3Health News:IRS Attack Exemplifies the Compounding Dangers of Stolen Personal Data 4Health News:IRS Attack Exemplifies the Compounding Dangers of Stolen Personal Data 5
... , PLAINVIEW, N.Y., July 17 Davis Vision, Inc., ... has already provided more than $200,000 to date in free vision ... exams and eyeglasses have been provided to more than 1,500 people ... bring our ,Focus on America, vision program to a variety of ...
... , WORCESTER, Mass., July 17 The ... property and casualty insurer, today announced the availability of a new product ... in assisted living facilities. , , ... , The coverage is more important than ever ...
... , , SKILLMAN, N.J., July ... technologies for community and hospital care, announced today it received first ... Advertising Effectiveness Awards for its Flexi-Seal((R) )Fecal Management System (FMS). ... Flexi-Seal((R)) FMS, a temporary containment device for patients with acute fecal ...
... , , HARTFORD, Conn., July 17 ... summer have more opportunities for hands-on, minds-on exploration and fun thanks ... , , Issued earlier this year, ... & crafts and athletic activities, to add new resources and programs ...
... journal- , , BELLEVILLE, ON, July 17 /PRNewswire-FirstCall/ ... technology-driven Canadian biopharmaceutical company, today announced that the results ... Company,s Escherichia coli (E. coli) O157 vaccine - Econiche(TM) ... Foodborne Pathogens and Disease (Vol. 6, Number 7, 2009), ...
... and for profit collaborate during tough economic times , ... sinking economy are thinking out of the box these days. In ... the same way except that their funding comes not from donors but ... Jungle Island decided to collaborate to attract patrons to visit the animal ...
Cached Medicine News:Health News:Davis Vision Provides More Than $200,000 in Free Vision Care Services 2Health News:Davis Vision Provides More Than $200,000 in Free Vision Care Services 3Health News:The Hanover Launches New Insurance Option to Protect Family Members in Assisted Living Facilities 2Health News:The Hanover Launches New Insurance Option to Protect Family Members in Assisted Living Facilities 3Health News:Flexi-Seal(R) Fecal Management System Receives 2008 Critical Care Nurse Advertising Effectiveness Award 2Health News:Flexi-Seal(R) Fecal Management System Receives 2008 Critical Care Nurse Advertising Effectiveness Award 3Health News:Hartford's Camp Courant Gets a 'Brick' Up on Summer Thanks to $100,000 Grant From The LEGO(R) Children's Fund 2Health News:Hartford's Camp Courant Gets a 'Brick' Up on Summer Thanks to $100,000 Grant From The LEGO(R) Children's Fund 3Health News:Econiche(TM) Vaccine Efficacy Summarized in July Issue of Foodborne Pathogens and Disease 2Health News:Econiche(TM) Vaccine Efficacy Summarized in July Issue of Foodborne Pathogens and Disease 3Health News:Econiche(TM) Vaccine Efficacy Summarized in July Issue of Foodborne Pathogens and Disease 4Health News:Econiche(TM) Vaccine Efficacy Summarized in July Issue of Foodborne Pathogens and Disease 5Health News:Econiche(TM) Vaccine Efficacy Summarized in July Issue of Foodborne Pathogens and Disease 6Health News:Fundraising in the Jungle 2
ACMI™ COAG Bipolar Laparoscopy Probes provide 360 of hemostatis, bipolar safety, blunt dissection, irrigation, and suction in one instrument....
... vitro Nucleic Acid Hybridization Assay ... Chemiluminescence for the Qualitative Detection ... 6,11,16,18,31,33,35,39,42,43,44,45,51,52,56,58,59 and 68 and Analysis ... Groups in Cervical Specimens: HPV ...
An In Vitro Nucleic Acid Hybridization Assay with Signal Amplification using Microplate Chemiluminescence for the Qualitative Detection of Human Papillomavirus (HPV) Types 16, 18, 31, 33, 35, 39, 45,...
... AS100 Analyzer is designed ... regardless of the sample ... launched in December 2004, ... in May 2005. Assays ...
Medicine Products: